Aldeyra Therapeutics, Inc. Share Price & Technical Analysis
ALDX · $1.55 (-2.52%)
Healthcare / Biotechnology
$1.55
-2.52%
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
0% return in May, -7% avg return in past 3 year May month.
-71% return in 2026, 34% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 4% | -69% | -12% | 0% | – | – | – | – | – | – | – | -71% |
| 25 | 2% | 0% | 12% | -53% | -19% | 81% | 32% | 18% | -10% | -2% | 8% | -4% | 64% |
| 24 | -11% | 13% | -11% | 18% | -2% | -15% | 18% | 45% | -5% | -2% | -8% | 2% | 41% |
| 23 | -16% | 13% | 46% | -4% | 0% | -11% | -4% | -7% | -11% | -75% | 40% | 25% | -3% |
| 22 | -10% | 11% | 7% | -31% | 3% | 29% | 25% | 40% | -25% | 2% | 2% | 23% | 76% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$103.75M
P/E ratio
—
52W high
$6.17
52W low
$1.07
Volume
4,75,196
Beta
1.15
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aldeyra Therapeutics, Inc. share price today?
- Aldeyra Therapeutics, Inc. (ALDX) last traded around $1.55 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALDX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALDX. Download the app for real-time alerts.
- How can I analyze Aldeyra Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.